Should I Buy RLAY? RLAY 2026 Analysis

Should You Buy Relay Therapeutics Inc (RLAY) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

7.710

1 Day change

0.78%

52 Week Range

9.040

Analysis Updated At

2026/01/26

Relay Therapeutics Inc (RLAY) is not a strong buy at the moment for a beginner, long-term investor with $50,000-$100,000 to invest. While there are some positive catalysts, such as hedge fund buying and an analyst upgrade with a higher price target, the company's weak financial performance, lack of recent news, and absence of strong trading signals make it less compelling for immediate investment. A 'hold' action is recommended until stronger signals or financial improvements emerge.

Technical Analysis

The stock's MACD is below 0 and negatively contracting, indicating bearish momentum. RSI is neutral at 34.224, and moving averages are converging, suggesting no clear trend. The stock is trading near its support level (S1: 7.165), with resistance at 8.21. Overall, the technical indicators do not provide a strong buy signal.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

The low put-call ratios indicate bullish sentiment in the options market, but the trading volume is low, limiting its reliability as a strong indicator.

Technical Summary

Sell

Buy

Positive Catalysts

Wells Fargo upgraded the stock to Overweight with a price target increase from $6 to $13, citing competitive data updates expected in
Hedge funds have significantly increased their buying activity by 352.49% over the last quarter.

Neutral/Negative Catalysts

The company's financial performance is weak, with declining net income (-15.84% YoY) and EPS (-31.75% YoY) in Q3
No recent news or event-driven catalysts to support a strong upward price movement.
No recent congress trading data or influential figure activity.

Financial Performance

In Q3 2025, Relay Therapeutics reported no revenue growth (0% YoY), a net income loss of -$74.15M (-15.84% YoY), and a significant EPS decline of -31.75% YoY. Gross margin remained at 100%, but the overall financial performance is weak.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Wells Fargo upgraded the stock to Overweight from Equal Weight with a price target increase to $13 (from $6), citing optimism about competitive data updates in 2026. This reflects a positive sentiment among analysts, but the impact is more long-term.

6 Analyst Rating

Wall Street analysts forecast RLAY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RLAY is 14.75 USD with a low forecast of 13 USD and a high forecast of 17 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

5 Buy

1 Hold

0 Sell

Strong Buy

Current: 7.650

Low

Averages

14.75

High

Current: 7.650

Low

Averages

14.75

High

Oppenheimer

analyst

Perform

Outperform

upgrade

$14

AI Analysis

2026-01-26

New

Reason

Oppenheimer

analyst

Price Target

$14

AI Analysis

2026-01-26

New

upgrade

Perform

Outperform

Reason

As previously reported, Oppenheimer upgraded Relay Therapeutics to Outperform from Perform with a $14 price target, citing the belief that gedatolisib's upcoming VIKTORIA-1 readout could be a tailwind for mutant-selective inhibitors like zovegalisib. The firm believes VIKTORIA-1 will underperform expectations, and may even fail, says the analyst, who thinks anything less than "teenage" mPFS for the gedatolisib triplet would create "a beatable bar for Relay," which is developing a competing triplet with zovegalisib.

Oppenheimer

Perform

Outperform

upgrade

$14

2026-01-26

New

Reason

Oppenheimer

Price Target

$14

2026-01-26

New

upgrade

Perform

Outperform

Reason

Oppenheimer upgraded Relay Therapeutics to Outperform from Perform with a $14 price target.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for RLAY

Unlock Now

RLAY Should I Buy

RLAY Should I Buy

Should You Buy Relay Therapeutics Inc (RLAY) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch